Markets:

Overview

News

Currencies

International

Treasuries

BioNTech SE - American Depositary Shares (NQ:BNTX)

103.88 -7.82 (-7.00%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 13, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about BioNTech SE - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

60 61 Next >

FDA Allows Resumption Of BioNTech/MediLink Therapeutics Partnered Phase 1 Study For Cancer Drug With Lower Dose ↗

August 19, 2024

FDA lifts partial hold on MediLink Therapeutics' phase 1 trial for HER3-targeting ADC BNT326/YL202 in advanced lung and breast cancer patients; trial resumes with revised dose limits following safety...

Via Benzinga

Unveiling 12 Analyst Insights On BioNTech ↗

August 19, 2024

Via Benzinga

Pfizer and BioNTech's Combo Shot Missed the Mark. Is It Time to Sell? ↗

August 19, 2024

A clinical-trial failure for Pfizer and BioNTech means Moderna is leading the race to develop a combo shot for the flu and COVID-19.

Via The Motley Fool

Why Pfizer Stock Slumped on Friday ↗

August 16, 2024

Investors were cautiously pessimistic about the latest news coming out of the company's lab.

Via The Motley Fool

Pfizer Slides Toward Sell Zone After BioNTech-Tied Covid/Flu Shot Misses Its Mark ↗

August 16, 2024

The company is now considering whether it needs to change up the vaccine to pass muster.

Via Investor's Business Daily

Pfizer, BioNTech's COVID-19/Flu Combo Vaccine Fails To Meet Key Goal In Late-Stage Study ↗

August 16, 2024

Pfizer and BioNTech report Phase 3 results for their combined mRNA vaccine against influenza and COVID-19. The trial met one of two primary immunogenicity objectives. Adjustments are planned to improve...

Via Benzinga

Navigating 12 Analyst Ratings For BioNTech ↗

August 01, 2024

Via Benzinga

Evaluating BioNTech: Insights From 12 Financial Analysts ↗

June 26, 2024

Via Benzinga

Struggling COVID-19 Vaccines From AstraZeneca, BioNTech/Pfizer, Moderna Cut Incidence Of Arterial Thromboses That Cause Heart Attacks, Strokes, British Study Shows ↗

August 13, 2024

COVID-19 vaccinations could lower the incidence of heart attacks and strokes, according to a new study by UK universities. The research shows a significant reduction in cardiovascular events among...

Via Benzinga

Long Covid Remains Diagnostic Mystery, Diagnosis Remains Elusive; National Institutes of Health-Funded Study Shows ↗

August 13, 2024

A recent NIH study reveals no clear diagnostic test for Long Covid, highlighting ongoing challenges in identifying and treating the condition affecting millions of Americans. Researchers continue to...

Via Benzinga

3 Biotech Stocks With Promising Drug Pipelines: August 2024 ↗

August 08, 2024

The biotech stocks with promising pipelines could see shares soar if drugs in late-stage trials get FDA approval.

Via InvestorPlace

This Cognizant Technology Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday ↗

August 07, 2024

Via Benzinga

BioNTech Se (BNTX) Q2 2024 Earnings Call Transcript ↗

August 05, 2024

BNTX earnings call for the period ending June 30, 2024.

Via The Motley Fool

Topics Earnings

US Stocks Trim Black Monday's Drops As Services Gauge Expands, Bond Gains Stall As Traders Reassess Fed Cuts: What's Driving Markets Monday? ↗

August 05, 2024

Global markets are experiencing intense volatility, and while it seemed like a Black Monday for Wall Street was inevitable following a 13% overnight tumble of Japan’s Nikkei 225, stock indices are...

Via Benzinga

Topics Economy

Moderna Lost 27% Of Its Value Over Two Days. It Just Crumbled Again. ↗

August 05, 2024

Moderna sustained a rare downgrade on Monday following its guidance cut for the year.

Via Investor's Business Daily

BNTX Stock Earnings: BioNTech Misses EPS, Misses Revenue for Q2 2024 ↗

August 05, 2024

BNTX stock results show that BioNTech missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.

Via InvestorPlace

BioNTech's Q2 Loss Widens Amid Low Demand For Its Pfizer-Partnered COVID-19 Vaccine, Increases R&D Spending On New Cancer Products ↗

August 05, 2024

BioNTech posted a significant Q2 2024 loss of 807.8 million euros. Sales dropped to 128.7 million euros as the demand for COVID-19 vaccines shifted. R&D expenses rose due to late-stage oncology...

Via Benzinga

Nasdaq, R2K Futures Tumble Over 4%, VIX Spikes Over 100%, Bitcoin Plunges Hard As Global Sell-Off Deepens Amid Recession Fears ↗

August 05, 2024

The stock market is on track to gap-open sharply lower on Monday as negative sentiment seen in the final two sessions of last week has carried over into the new week. The index futures were all sharply...

Via Benzinga

Topics Economy Stocks

What's Going On With BioNTech (BNTX) Shares? ↗

August 01, 2024

BioNTech shares are trading lower by 5.3% during Thursday's session. Vaccine stocks are down after Moderna cut its 2024 outlook due to weak EU sales and increased U.S. competition.

Via Benzinga

Moderna Slashes Its Outlook On 'Very Low' European Sales Despite Quarterly Beat ↗

August 01, 2024

Moderna delivered nearly double the sales analysts expected in the second quarter.

Via Investor's Business Daily

Week In Review: Nanjing Triastek Partners With BioNTech In A $1.2 Billion Drug Development Deal ↗

July 27, 2024

Triastek will develop oral RNA therapeutics with Germany’s BioNTech based on its 3D printing technology. Triastek will receive a $10 million upfront payment and up to $1.2 billion in milestones, plus...

Via Talk Markets

European Commission Faces Court Criticism Over COVID Vaccine Contract Transparency Ahead Of Vote on Ursula Von Der Leyen's Reappointment ↗

July 17, 2024

European Commission faces scrutiny over COVID vaccine contract transparency ahead of key vote. Legal challenges and implications discussed.

Via Benzinga

GSK Buys Full Rights To Investigational Covid-19 And Influenza Vaccines From CureVac For Around $1.5B ↗

July 03, 2024

GSK and CureVac restructured their collaboration into a new licensing agreement, prioritizing mRNA vaccine development. GSK gains full control of vaccine candidates for influenza and COVID-19, while...

Via Benzinga

London High Court Ruling Fuels Pfizer And Moderna Legal Dispute Over COVID-19 Vaccine Patents ↗

July 02, 2024

Pfizer and Moderna continue their legal battle over COVID-19 vaccine patents following a mixed ruling by London's High Court, with potential appeals on the horizon and significant financial stakes...

Via Benzinga

Topics Intellectual Property

3 Nasdaq Stocks to Sell in July Before They Crash & Burn ↗

July 02, 2024

These are three Nasdaq stocks to sell before their value plunges even further due to broader economic pressures.

Via InvestorPlace

Surprise! 3 Stocks That Are Outperforming Nvidia in 2024. ↗

July 01, 2024

There are more marketplace opportunities than just AI which is why these stocks that are outperforming Nvidia have done so well.

Via InvestorPlace

Topics Artificial Intelligence

3 Dividend Stocks Yielding Over 3% With Multi-Decade Payout Growth Streaks ↗

July 01, 2024

Explore three high-yield dividend stocks that not only offer yields of 3% or more but also boast multiple decades of payout growth.

Via InvestorPlace

AbbVie/Genmab's Epkinly FDA Approval Is A Positive Step, Analyst Says Additional Expansion Opportunities Underway ↗

June 27, 2024

The FDA has approved Epkinly as the first subcutaneously administered bispecific antibody for adults with relapsed or refractory follicular lymphoma after two or more lines of prior therapy.

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

June 24, 2024

Via Benzinga

GameStop And First Solar Were Among The 10 Biggest Large Cap Losers Last Week (June 16-June 22): Are These In Your Portfolio? ↗

June 23, 2024

10 worst-performing large-cap stocks last week: GME, ENPH, ALB, BNTX, ALGN, FLSR, BALL, MBLY, BLD, JBL. Are they in your portfolio?

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

60 61 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.